Since PTX3 acts as a natural antagonist for FGFs [46], the changes in PTX3 level may determine the angiogenic and tumorigenic potential of osteoblastic prostate cancer cells, presumably by inhibiting bone-forming activity exerted by FGFs [46]. The gene discussed is PTX3; the disease is Familial prostate cancer.